## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Confirmation No.: 6157

Alberto Haces Art Unit: 1616

Appl. Ser. No. 10/762,914 Examiner: Holt, Andriae M.

Filed: January 21, 2004 Atty. Docket: IVGN 114.5 DIV

For: **Highly Packed Polycationic** 

Ammonium, Sulfonium and

**Phosphonium Lipids** 

## **SUBMISSION MADE WITH AN RCE:**

## **Information Disclosure Statement**

Mail Stop RCE Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

In response to the Notice of Allowance and Fee(s) Due mailed **June 30, 2008**, Applicants have filed herewith in a separate paper a request for continued examination (RCE) under 37 C.F.R. § 1.114. In relation thereto, Applicants respectfully request entry and consideration of the instant Submission, which includes an Information Disclosure Statement made under 37 C.F.R. §§ 1.97 and 1.98.

Applicants hereby authorize the Commissioner to charge Deposit Account No. 50-3994 in the amount of \$180.00, the fee set forth under 37 C.F.R. § 1.17(p). Applicants do not believe that any additional fees are due for filing the instant Information Disclosure Statement. However, in the unlikely event that any such fees are due, the Commissioner is hereby authorized to charge the same to Deposit Account No. 50-3994, with reference to our matter IVGN 114.5 DIV.

Pursuant to 37 CFR § 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the Information Disclosure

Docket No. IVGN 114.5 DIV - 2 -Appl. No. 10/762,914

Statement is, or is considered to be, material to patentability as defined in § 1.56 (b). Further, this Information Disclosure Statement is not to be construed as a representation that: (1) a complete search has been made of the prior art; (2) the cited information constitutes prior art to the subject invention; or (3) no better information than the information cited in the Information Disclosure Statement are available.

Applicants respectfully request that the cited information be considered by the Examiner and made of record in the above-identified application. The Examiner is requested to initial and return the enclosed PTO/SB08 forms in accordance with MPEP §609. Following consideration of the cited information, the Examiner is respectfully requested to reissue a Notice of Allowance and Fee(s) Due for the above-captioned application.

Respectfully submitted,

/James K. Blodgett/ James K. Blodgett, Reg. No. 48,480 Agent for Applicants 608-204-5343

Alberto Haces

Date: September 29, 2008

Invitrogen Corporation Customer No. 52059